A novel ultra-short-acting benzodiazepine (BDZ), remimazolam (CNS 7056), has been
designed by 'soft drug'development to achieve a better sedative profile than that of the …

A program to identify novel intravenous sedatives with a short and predictable duration of
action was initiated in the late 1990's by Glaxo Wellcome. The program focussed on the …

Remimazolam (CNS7056) is a novel benzodiazepine for intravenous sedation; it has an
ultra-short duration of action and was recently approved for use in procedural sedation and …

Background Intraoperative and postoperative hypotension occur commonly and are
associated with organ injury and poor outcomes. Changes in arterial blood pressure (BP) …

Background Remimazolam besylate is a newer benzodiazepine with characteristics of quick
onset of effects, short maintenance and recovery times without accumulation in tissues. This …

Ciprofol is a propofol analogue with improved pharmacokinetic properties. A multi‐centre,
non‐inferiority trial was conducted to compare the deep sedation properties of ciprofol and …

Background The bispectral index (BIS) value during general anesthesia with the newly
developed anesthetic remimazolam is reported to be relatively high; however, the reason for …

Abstract Background and Aim Remimazolam tosilate (RT) is under evaluation as a sedative
for endoscopic procedures. Herein, we aimed to evaluate safety including cognition …

Remimazolam is a new ultrashort-acting benzodiazepine with fast onset, quick recovery,
and few side effects, such as hypotension and respiratory depression. It is expected to be …

Objective To explore the anesthetic and analgesic effects of remimazolam and propofol in
elderly patients undergoing hip replacement and their effects on respiratory and circulatory …